An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.
about
Mitochondrial apoptosis and BH3 mimeticsTargeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenograftsBM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivoDetailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma CellsGene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor LineagesMCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells.Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL MicroenvironmentMcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals.Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer.Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway.Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsmicroRNA-10b Is Overexpressed and Critical for Cell Survival and Proliferation in MedulloblastomaCyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimeticsmiR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemiaLoss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1.BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells.Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.Toward a cure for chronic lymphocytic leukemia: an attack on multiple frontsMLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylationDevelopment of venetoclax for therapy of lymphoid malignancies.Targeting the B-cell lymphoma/leukemia 2 family in cancer.Biomarkers of therapeutic response to BCL2 antagonists in cancer.CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia.Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.Lipidoid nanoparticle mediated silencing of Mcl-1 induces apoptosis in mantle cell lymphoma.Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.Gene expression profiling of tumor-initiating stem cells from mouse Krebs-2 carcinoma using a novel marker of poorly differentiated cellsDuvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).Microarray determination of Bcl-2 family protein inhibition sensitivity in breast cancer cells.The BH3-only protein Puma plays an essential role in p53-mediated apoptosis of chronic lymphocytic leukemia cells.
P2860
Q28069552-758112D2-2EBC-40A1-9483-47930AB833CDQ28538631-288D0D7B-3D2E-4ADE-A4F5-9CD1F0EC9E35Q28539452-88274EBA-7CD5-4751-88DC-A0D7A718789BQ28547322-9E2A0EDB-ADE6-47B4-99D9-9A3BA8C008ABQ28548165-70B30720-5362-4DAB-9A28-58A8A4A8AD67Q33419789-A35AE630-7C3D-46F8-AF7D-54E076F8C4B4Q34177843-8BAD5133-C5B7-4EEF-84A0-34817794E713Q35165195-6C8F4BD5-E34C-49D8-9715-9255DD08FD09Q35212727-684C66B2-8715-4232-98D2-FB0731D6FDB8Q35606359-80A25864-7FBE-47CE-BD1E-FD17F7E9CCDEQ35938054-68E37CDA-889E-4214-9F21-7453B2E1C576Q35951381-14B56BC1-D8CA-4104-BAE3-89FE8136C8E4Q35966191-423AE05A-2721-4150-BD33-B1E61C2CEDE0Q35979299-32D18642-522C-4525-9E49-5A97663918D2Q36057611-D7F56C89-59E9-44BB-90C4-67E54637731EQ36083620-5EDB7885-714E-4E34-8DFF-D5D5E0867BEDQ36231912-6CDB0BEE-4029-4865-BBA4-F92C1ACECCB1Q36247617-2988955B-7EB7-4451-9A12-44259687CEDCQ36276017-34D382E9-D0B9-4469-AEC2-E474CEF90DFFQ36349985-F22DE699-0663-4A9E-83AA-A1488C8DCF5BQ36546429-CF1D69C5-704D-4D89-B6F1-EFA5A920A72EQ36751571-EB0BE52E-B5EE-4509-9EEC-6AD7950CDC24Q36857524-FADD135E-ECA0-4373-A071-1D0E805FB073Q36907112-F88D39FE-094A-4784-8532-369EBDC84F3BQ37092954-FFE72CF2-5364-4152-BD4D-E115D2FF2822Q37542942-6D6A9CFA-3E64-458A-A939-D016B4ABE9A8Q37676956-E73E39AB-F7D2-4CF6-BB38-1FCC07C946C2Q37702281-FA1BA585-F1DD-4C01-9CA1-2932446A75ABQ38014808-EB2F2CB3-25E4-452F-9CFA-53209F7D24D3Q38047846-0D0210D9-D9F2-4D6F-93CE-5A9CC2308716Q38704051-C2EAB079-78DD-4BC1-A504-FF4872D51388Q38782374-9F74D9BA-DA4A-4369-B6FF-847C3EB5713CQ38782716-41B741BE-3D11-4D36-9A41-81C2AA100CE6Q38825797-E03F2C5E-6EAB-4329-AEA5-7E623935D05BQ38826234-6B751B2F-AE62-4A08-ABCB-96314FBA5C4BQ39031813-B36E0286-DB56-4713-8C66-F97C54ACE9C9Q39056377-0C507F8B-9A59-49E0-B3D0-5C244E77627AQ39065374-55B5A375-056F-438F-B6B0-5CF87902673CQ39168078-55DD2918-0BDA-45CC-BF2E-B0D04F0EAC4FQ39177637-1440088D-FCE6-4335-A74E-94C4B35F7E55
P2860
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
An antiapoptotic BCL-2 family ...... mphocytic leukemia to ABT-737.
@ast
An antiapoptotic BCL-2 family ...... mphocytic leukemia to ABT-737.
@en
type
label
An antiapoptotic BCL-2 family ...... mphocytic leukemia to ABT-737.
@ast
An antiapoptotic BCL-2 family ...... mphocytic leukemia to ABT-737.
@en
prefLabel
An antiapoptotic BCL-2 family ...... mphocytic leukemia to ABT-737.
@ast
An antiapoptotic BCL-2 family ...... mphocytic leukemia to ABT-737.
@en
P2093
P2860
P1433
P1476
An antiapoptotic BCL-2 family ...... ymphocytic leukemia to ABT-737
@en
P2093
Brian T Hill
Janet A Houghton
Jaroslaw P Maciejewski
Jennifer Devecchio
Kamini Singh
Lisa A Rybicki
Matt Kalaycio
Sayer Al-Harbi
Suparna Mazumder
P2860
P304
P356
10.1182/BLOOD-2011-03-340364
P407
P577
2011-07-19T00:00:00Z